Sorrento's R&D wuxuu diiradda saarayaa wadida hal-abuurka COVID-19, daaweynta kansarka, xakameyn buuxda oo xanuunka iyo cudurrada difaaca jirka

Barnaamijyada Muhiimka ah	Muujin	Diyaarsanaan	Wejiga I	Wajiga labaad	Marxaladda III/Pivotal	FDA Approval
Barnaamijyada COVID-19
COVISTIX™ (diagnostic) Tijaabada Antigen-ka degdega ah 0%* Oggolaanshaha Isticmaalka Degdegga ah (EUA) ee Mexico (COFEPRIS), Brazil (ANVISA), iyo CE lagu calaamadeeyay Yurub COVIMARK™ (diagnostic) Tijaabada Antigen-ka degdega ah 0%* Codsiga lagu soo gudbiyay Mareykanka iyo Kanada ee Ogolaanshaha Isticmaalka Degdegga ah (EUA) COVISHIELD™ (daawaynta) Dhexdhexaadinta Antibody (IN) ee Bukaan-socodka iyo Bukaan-jiifka 40%* COVISHIELD™ (daawaynta) Dhexdhexaadinta Antibody (IV) ee Bukaan-socodka iyo Bukaan-jiifka 20%* FUJOVEE™ (Abivertinib) COVID-19 daran oo ku jira Bukaanka ICU 82%* Tijaabada Muhiimka ah ee la sugayo nadiifinta FDA OQORY™ (COVI-MSC) ARDS oo ay ugu wacan tahay COVID-19 ee Bukaannada ICU 82%* Tijaabada Muhiimka ah ee Brazil Mpro Kahortagga (kaniiniga afka) Anti-viral 40%* Omicron mRNA Tallaalka Tallaalka 20%*
Barnaamijyada Muhiimka ah	Muujin	Diyaarsanaan	Wejiga I	Wajiga labaad	Marxaladda III/Pivotal	FDA Approval
immunotherapy
FUJOVEE™ (Abivertinib) NSCLC 82%* FUJOVEE™ (Abivertinib) Lymphomas Unugyada B 60.2%* FUJOVEE™ (Abivertinib) Prostate 20%* FUJOVEE™ (Abivertinib) lupus 20%* FUJOVEE™ (Abivertinib) MS 20%* FUJOVEE™ (Abivertinib) GvHD 20%* PD-L1 (Socazolimab)* SCLC 82%* *Iskaashiga Lee's Pharm ee Shiinaha PD-L1 (STI-3031)** Kansarka afka ilmo-galeenka 82%* ** gudaha Maraykanka iyo iyada oo lala kaashanayo ImmuneOncia ee Kuuriya CD47 Burooyin Adag 40%* CD38 DAR-T Meelo badan 40%* CD38 ADC Amyloidosis, Multiple Myeloma, T-ALL, iyo hunguriga 40%* TROP2 ADC* Burooyin Adag 40%* * Shiinaha Seprehvec™ oncolytic fayraska Burooyinka adag; Burooyinka CNS 40%* BCMA ADC Burooyinka dareeraha ah 20%* Bevacizumab-ADNAB™ Kansarka endometrial 40%* Iyadoo lala kaashanayo Mayo Clinic Bevacizumab-ADNAB™ Kansarka Ovarian 40%* Iyadoo lala kaashanayo Mayo Clinic Rituximab-ADNAB™ Lymphomas-unugyada B 40%* Iyadoo lala kaashanayo Mayo Clinic
Barnaamijyada Muhiimka ah	Muujin	Diyaarsanaan	Wejiga I	Wajiga labaad	Marxaladda III/Pivotal	FDA Approval
Xanuun
ZTlido™ 1.8% Neuralgia postherpetic - PHN 99.8%* SP-102 (SEMDEXA) Lumbar Radicular/Sciatica Xanuun 82%* SP-103 (Nidaamka Mawduuca Lidocaine 5.4%) Dhabar-xanuun daran 20%* SP-104 (Qiyaas hoose oo Naltrexone ah oo dillaacay oo daahay) fibromyalgi 20%* RTX (resiferatoxin) Cirbadda epidural Xannuun aan la daweyn karin oo ku jira Kansarka Sare 60.3%* Magacaabista agoonta RTX (resiferatoxin) Dariiqa articular Dhexdhexaad ilaa Daran OA Xanuun Jilibka ah 60.2%*
Barnaamijyada Muhiimka ah	Muujin	Diyaarsanaan	Wejiga I	Wajiga labaad	Marxaladda III/Pivotal	FDA Approval
Bixinta Lymphatic
Sofusa® anti-TNF Autoimmune (RA) 40%* Sofusa® anti-PD-1 Cudurka T-Cell Lymphoma (CTCL) 40%* Sofusa® anti-CTLA-4 Melanoma 40%* Iyadoo lala kaashanayo Mayo Clinic

Barnaamijyada COVID-19
Barnaamijyada Muhiimka ah (Tilmaan)	Phase
COVISTIX™ (diagnostic) FDA EUA COVIMARK™ (diagnostic) FDA EUA COVISHIELD™ (daawaynta) PH I COVISHIELD™ (daawaynta) Diyaarsanaan FUJOVEE™ (Abivertinib) Ph III OQORY™ (COVI-MSC) Ph III Mpro Inhibitor (kaniiniga afka) (ka-hortagga fayraska) Ph I Omicron mRNA Tallaalka (tallaal) Diyaarsanaan

immunotherapy
Barnaamijyada Muhiimka ah (Tilmaan)	Phase
FUJOVEE™ (Abivertinib) (NSCLC) Ph III FUJOVEE™ (Abivertinib) (Lymphomas Unugyada B) Ph II FUJOVEE™ (Abivertinib) (Prostate) Diyaarsanaan FUJOVEE™ (Abivertinib) (Lupus) Diyaarsanaan FUJOVEE™ (Abivertinib) (MS) Diyaarsanaan FUJOVEE™ (Abivertinib) (GvHD) Diyaarsanaan PD-L1 (Socazolimab)*(SCLC) Ph III PD-L1 (STI-3031)** (Kansarka ilmo-galeenka) Ph III CD47 (Buro Adag) Ph I CD38 DAR-T (Multiple Myeloma) Ph I CD38 ADC (Amyloidosis, Multiple Myeloma, T-ALL, iyo hunguriga) Ph I TROP2 ADC* (Buro Adag) Ph I Seprehvec™ oncolytic fayraska (Buro adag; Burooyinka CNS) PH I BCMA ADC ( Burooyinka dareeraha ah) Diyaarsanaan Bevacizumab-ADNAB™ Kansarka endometrial Ph I Bevacizumab-ADNAB™ (Kansarka ugxansidaha) Ph I Rituximab-ADNAB™ (Lymphomas B-cell) Ph I

Xanuun
Barnaamijyada Muhiimka ah (Tilmaan)	Phase
ZTlido™ 1.8% (Postherpetic Neuralgia - PHN) FDA Approval SP-102 (SEMDEXA) Ph III SP-103 (Nidaamka Mawduuca Lidocaine 5.4%) Diyaarsanaan SP-104 (Qiyaas hoose oo Naltrexone ah oo dillaacay oo daahay) Diyaarsanaan RTX (resiniferatoxin) cirbadeynta epidural (Xanuun aan la daweyn karin oo ku jira Kansarka Sare) Ph II RTX (resiniferatoxin) Dariiqa xididada hoose (Dhexdhexaad ilaa Daran OA Xanuun Jilibka ah) Ph II

Bixinta Lymphatic
Barnaamijyada Muhiimka ah (Tilmaan)	Wajiga labaad
Sofusa® anti-TNF (Autoimmune RA) Ph I Sofusa® anti-PD-1 (Cutaneous T-Cell Lymphoma (CTCL)) Ph I Sofusa® anti-CTLA-4 (Melanoma) Ph I